600420.SH
国药现代
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.45
−0.12%Year over year
Reported trailing growth
- Revenue
- -15.4%
- EBITDA
- —
- EBIT
- -38.7%
- EPS
- -35.5%
- Free cash flow
- -53.3%
- Operating cash flow
- -44.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -10.3%
- EBITDA
- +4.2%
- EBIT
- +10.8%
- Net income
- +14.5%
- EPS
- +4.7%
- Free cash flow
- -17.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026